Thalidomide is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 41 clinical trials, of which 38 were completed, and 3 are ongoing.
Thalidomide possesses immunomodulatory, anti-inflammatory and antiangiogenic properties. By activating cereblon (a component of a cullin ring E3 ubiquitin ligase enzyme complex), thalidomide mediates the ubiquitination and subsequent degradation of the substrate proteins, leading to direct cytotoxic and immunomodulatory effects. It also acts by suppressing the excessive tumor necrosis factor-alpha (TNF-alpha) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration.
The revenue for Thalidomide is expected to reach a total of $706m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Thalidomide NPV Report.
Thalidomide is currently owned by Bristol-Myers Squibb.
Thalidomide (Thalomid) is an immunomodulatory imide drug (IMiD). It is formulated as hard gelatin capsules for oral route of administration. It is indicated in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). It can also be used as maintenance therapy for the prevention and suppression of the cutaneous manifestations of ENL recurrence. Thalidomide in combination with melphalan and prednisone (MPT) is indicated for the treatment of patients with previously untreated multiple myeloma who are 65 years of age or older.
Thalidomide was under development for the treatment of myelodysplastic syndrome, leukemias, glioblastoma, liver cancer, kidney cancer, prostate cancer, Kaposi's sarcoma, cancer cachexia, sarcoidosis, scleroderma, , Crohn's disease, ulcerative colitis, colorectal cancer, graft versus host disease, AIDS-related conditions, including cachexia, recurrent aphthous stomatitis, chronic diarrhea, and clinical manifestations of mycobacterial infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – Thalidomide
|Highest Development Stage|